Literature DB >> 11357798

Pharmacology of antidepressants.

E Richelson1.   

Abstract

Presently in the United States, 21 compounds have been approved by the Food and Drug Administration as antidepressants. Two additional drugs marketed outside the United States as antidepressants have been approved for obsessive-compulsive disorder. Nearly one half of all these compounds became available within the past 12 years, whereas the first antidepressant was available more than 40 years ago. After the clinical aspects of depression are introduced in this article, the pharmacology of the newer generation drugs is reviewed in relationship to the older compounds. The information in this review will help clinicians treat acute depression with pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11357798     DOI: 10.4065/76.5.511

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  35 in total

1.  Regulation of rat cortical 5-hydroxytryptamine2A receptor-mediated electrophysiological responses by repeated daily treatment with electroconvulsive shock or imipramine.

Authors:  Gerard J Marek
Journal:  Eur Neuropsychopharmacol       Date:  2008-02-21       Impact factor: 4.600

Review 2.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

3.  Cortical 5-hydroxytryptamine2A-receptor mediated excitatory synaptic currents in the rat following repeated daily fluoxetine administration.

Authors:  Gerard J Marek
Journal:  Neurosci Lett       Date:  2008-04-24       Impact factor: 3.046

4.  Extent and Predictors of Potentially Inappropriate Antidepressant Use Among Older Adults With Dementia and Major Depressive Disorder.

Authors:  Sandipan Bhattacharjee; Jeannie K Lee; Asad E Patanwala; Nina Vadiei; Daniel C Malone; Shannon M Knapp; Wei-Hsuan Lo-Ciganic; William J Burke
Journal:  Am J Geriatr Psychiatry       Date:  2019-02-07       Impact factor: 4.105

Review 5.  Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement.

Authors:  Alex Mu; Erica Weinberg; Dwight E Moulin; Hance Clarke
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

Review 6.  A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2010-04-29       Impact factor: 7.616

7.  Anesthetic efficacies of intrapapillary injection in comparison to inferior alveolar nerve block for mandibular premolar extraction: a randomized clinical trial.

Authors:  Duangkamon Wongpang; Anupong Makeudom; Thanapat Sastraruji; Sakornrat Khongkhunthian; Suttichai Krisanaprakornkit; Chayarop Supanchart
Journal:  Clin Oral Investig       Date:  2019-05-21       Impact factor: 3.573

8.  Prolonged post-dural puncture headache in a patient during treatment with selective serotonin reuptake inhibitor: a case report and animal experiment.

Authors:  Takashi Kawano; Tetsuya Takahashi; Noriko Kitaoka; Masataka Yokoyama
Journal:  J Anesth       Date:  2014-04-26       Impact factor: 2.078

9.  Triple reuptake inhibitors: a premise and promise.

Authors:  David M Marks; Chi-Un Pae; Ashwin A Patkar
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

10.  Triple reuptake inhibitors: the next generation of antidepressants.

Authors:  David M Marks; Chi-Un Pae; Ashwin A Patkar
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.